On this page you will find our recommendations sorted by BNF chapter.

Appraisal Reports are available to stakeholders on request.

Where a decision is >24 months old; these are highlighted in red. If you are a clinician working within the NTAG region and would like to prioritise an old decision for re-review please contact the professional secretary on nuth.nyrdtc.rxsupp@nhs.net

Title Documents Decision Date
Agomelatine (Valdoxan®) for depression (NETAG) Recommendation Recommended for the treatment of depression only following an adequate trial of at least three alternative antidepressant drugs at maximally tolerated doses 13/07/2010
Buprenorphine prolonged release injection for opioid dependence Recommendation Recommended as alternative option for the management of opioid dependence after oral methadone and/or oral buprenorphine 07/09/2021
Doxylamine/Pyridoxine (Xonvea®) for nausea & vomiting in pregnancy Recommendation Not currently recommended pending further national guidance 23/02/2021
e-Voke® electronic cigarette for smoking cessation Recommendation Not recommended 05/04/2016
Lurasidone (Latuda®▼) for the treatment of schizophrenia in adults and adolescents aged 13 years and over Recommendation Recommended as an option only for the treatment of schizophrenia in adults and adolescents aged 13 years and older meeting the criteria in the recommendation 07/09/2021
Lycra Garments for the management of cerebral palsy and other neurological or musculoskeletal conditions Recommendation Not recommended 25/02/2020
Perampanel (Fycompa®) for Partial-onset (focal) epilepsy (NETAG) Recommendation Recommended only when other treatment options recommended by NICE have been tried or fully considered 08/06/2021
Pitolisant (Wakix®) for the treatment of narcolepsy with or without cataplexy in adults Recommendation Appeal Appraisal Pitolisant (Wakix®) Treatment Pathway Recommended as per the regionally agreed guidance 22/02/2022
Qutenza® (capsaicin patch) for neuropathic pain (updated) Recommendation Qutenza® Treatment Pathway Recommended as a fourth line agent in line with treatment pathway 06/06/2017
Sativex® for the treatment of non-MS pain Recommendation Not recommended 25/02/2020
Sodium oxybate(Xyrem®) for Narcolepsy with Cataplexy in adult patients (updated) NTAG Decision Summary - Sodium Oxybate for narcolepsy - updated Nov 2022 - final Recommended 15/11/2022
Solriamfetol for obstructive sleep apnoea in adults Recommendation Not recommended for use ahead of NICE TA 08/12/2020
Transcutaneous vagus nerve stimulation for treatment of cluster headache and migraine Recommendation Recommended for Cluster Headache only (updated) 08/06/2021
Voke® Inhaler Nicotine Replacement Therapy for Smoking Cessation Recommendation Not recommended as a stop smoking aid on the NHS or for prescribing by GPs 25/02/2020

New

09/05/2023
North East North Cumbria (NENC) ICB Medicines Committee Position Statement on Prescribing in Persistent Pain NENC ICB position-statement-non-palliative-care-use-of-opiates update April 23 Approved 18/04/2023